Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(3.54)
# 875
Out of 5,127 analysts
35
Total ratings
57.14%
Success rate
30.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Reiterates: Overweight | n/a | $164.01 | - | 5 | May 15, 2025 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $4.61 | - | 4 | May 15, 2025 | |
| INSM Insmed | Reiterates: Overweight | n/a | $170.27 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $4.38 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint | Reiterates: Overweight | n/a | $17.08 | - | 6 | Jun 20, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $1.49 | +34.23% | 2 | Aug 31, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $7.53 | +338.25% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $2.10 | +114.29% | 2 | May 17, 2023 | |
| AYTU Aytu BioPharma | Maintains: Overweight | $220 → $100 | $2.66 | +3,659.40% | 2 | May 17, 2022 |
Belite Bio
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $164.01
Upside: -
Precigen
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.61
Upside: -
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $170.27
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.38
Upside: -
EyePoint
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.08
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $1.49
Upside: +34.23%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $7.53
Upside: +338.25%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.10
Upside: +114.29%
Aytu BioPharma
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $2.66
Upside: +3,659.40%